ViaTris Inc. (VTRS): Business Model Canvas [Jan-2025 Mise à jour]

Dans le monde dynamique de l'innovation pharmaceutique, ViaTris Inc. (VTRS) émerge comme une force transformatrice, mélangeant stratégiquement les prouesses de la fabrication mondiale, divers portefeuilles de médicaments et un engagement en matière de soins de santé accessibles. En intégrant magistralement les héritages de la division UpJohn de Mylan et Pfizer, cette puissance pharmaceutique a conçu un modèle commercial unique qui offre de haute qualité, Médicaments rentables dans plusieurs domaines thérapeutiques, révolutionnant la façon dont les patients et les prestataires de soins de santé abordent les solutions de traitement abordables dans le monde.

ViaTris Inc. (VTRS) - Modèle commercial: partenariats clés

Alliance stratégique avec les fabricants pharmaceutiques du monde entier

ViaTris maintient des alliances stratégiques avec plus de 250 fabricants pharmaceutiques dans 60 pays. Le réseau de fabrication mondial de l'entreprise comprend:

Région	Sites de fabrication	Capacité de production annuelle
Amérique du Nord	12 sites	8,5 milliards d'unités
Europe	9 sites	6,2 milliards d'unités
Asie-Pacifique	15 sites	10,3 milliards d'unités

Collaboration avec les distributeurs mondiaux de santé

ViaRris s'associe aux principaux distributeurs de soins de santé dans le monde, notamment:

• McKesson Corporation
• Amerisourcebergen
• Santé cardinale
• Henry Schein

Le réseau de distribution couvre 165 pays avec plus de 7 500 canaux de distribution.

Partenariat avec des installations de production de médicaments génériques

ViaRris collabore avec plus de 150 installations génériques de production de médicaments dans le monde. Les principaux partenariats de production comprennent:

Partenaire	Focus de la production	Volume annuel
Pfizer Centresource	Ingrédients pharmaceutiques actifs	2,3 milliards d'unités
Fabrication de Mylan	Pharmaceutiques génériques	4,1 milliards d'unités

Accords de recherche et de développement

ViaRris a des collaborations de R&D avec 45 établissements universitaires dans le monde, notamment:

• Institut de technologie du Massachusetts
• Université de Stanford
• Université Johns Hopkins
• Université de Californie, San Francisco

Investissement annuel de R&D: 1,2 milliard de dollars

Coentreprises avec des sociétés pharmaceutiques internationales

ViaRris a établi des coentreprises avec plusieurs sociétés pharmaceutiques internationales:

Partenaire	Focus de coentreprise	Valeur d'investissement
Biocon (Inde)	Développement des biosimilaires	300 millions de dollars
Lupine Limited	Extension de médecine générique	250 millions de dollars

ViaTris Inc. (VTRS) - Modèle d'entreprise: Activités clés

Fabrication pharmaceutique générique et spécialisée mondiale

Installations de fabrication sur 6 continents, avec 28 sites de fabrication dans le monde. Capacité de production totale d'environ 67 milliards de doses par an.

Région de fabrication	Nombre de sites	Capacité de production annuelle
Amérique du Nord	12	25 milliards de doses
Europe	8	18 milliards de doses
Asie-Pacifique	6	15 milliards de doses
Autres régions	2	9 milliards de doses

Recherche et développement pharmaceutiques

Investissement en R&D de 1,2 milliard de dollars en 2023, en se concentrant sur des génériques complexes et des médicaments spécialisés.

• Programmes de recherche actifs dans 15 domaines thérapeutiques
• Plus de 250 projets de recherche en cours
• Portefeuille de brevets d'environ 7 500 brevets actifs

Distribution et commercialisation des produits pharmaceutiques

Réseau de distribution couvrant plus de 165 pays, avec un chiffre d'affaires annuel de 16,6 milliards de dollars en 2023.

Canal de distribution	Portée du marché	Contribution des revenus
Pharmacies de vente au détail	120 pays	9,4 milliards de dollars
Systèmes hospitaliers	85 pays	4,2 milliards de dollars
Direct au patient	45 pays	3 milliards de dollars

Contrôle de la qualité et conformité réglementaire

Conformité aux normes réglementaires dans plusieurs juridictions, notamment les directives de la FDA, de l'EMA et de l'OMS.

• Passé 127 inspections réglementaires en 2023
• Zéro violations de conformité majeure
• Certification CGMP entretenue sur tous les sites de fabrication

Intégration des opérations de division Upjohn de Mylan et Pfizer

Intégration de la fusion terminée avec des économies de synergie totale de 1 milliard de dollars d'ici la fin de 2023.

Métrique d'intégration	Valeur
Coût total d'intégration	2,3 milliards de dollars
Économies de synergie	1 milliard de dollars
Base d'employés combinés	37,000
Portefeuille de produits combinés	1 400+ médicaments

ViaTris Inc. (VTRS) - Modèle d'entreprise: Ressources clés

Infrastructures de fabrication pharmaceutique mondiale

ViaRris exploite 37 sites de fabrication dans le monde sur 6 continents. La capacité de fabrication totale atteint 25 milliards de doses par an.

Emplacement de fabrication	Nombre de sites	Capacité de production annuelle
États-Unis	12	8,5 milliards de doses
Inde	9	6,2 milliards de doses
Autres emplacements internationaux	16	10,3 milliards de doses

Portfolio diversifié de médicaments génériques et de marque

ViaTris maintient un portefeuille d'environ 1 400 produits approuvés dans plusieurs zones thérapeutiques.

• Médicaments génériques: 1 100 produits
• Médicaments de marque: 300 produits
• Couverture dans 165 pays

Propriété intellectuelle et portefeuille de brevets

En 2023, ViaRris détient 7 500 brevets mondiaux dans diverses technologies et formulations pharmaceutiques.

Catégorie de brevet	Nombre de brevets
Formulations pharmaceutiques	3,200
Processus de fabrication	2,100
Technologies de livraison	2,200

Travaillerie qualifiée avec une expertise pharmaceutique

Compte total des employés: 37 000 à l'échelle mondiale dans tous les fonctions de recherche, de fabrication, de vente et d'administration.

• Employés titulaires de diplômes avancés: 22% (8 140 employés)
• Chercheur les chercheurs: 1 500
• Représentation mondiale de la main-d'œuvre: 50+ nationalités

Capacités avancées de recherche et de développement

Investissement annuel de R&D: 1,2 milliard de dollars en 2023.

Zone de focus R&D	Investissement	NOUVEAUX MOLcules développements
Développement de médicaments génériques	650 millions de dollars	45 nouvelles molécules génériques
Recherche pharmaceutique de marque	400 millions de dollars	12 nouvelles formulations de marque
Technologies de livraison avancées	150 millions de dollars	8 nouvelles plateformes de livraison

ViaTris Inc. (VTRS) - Modèle d'entreprise: propositions de valeur

Solutions de soins de santé abordables et accessibles

ViaTris a déclaré un chiffre d'affaires total de 4,7 milliards de dollars au troisième trimestre 2023, en se concentrant sur la fourniture de solutions pharmaceutiques rentables dans le monde.

Catégorie de produits	Part de marché mondial	Prix ​​moyen
Médicaments génériques	12.3%	15 $ - 45 $ par ordonnance
Spécialité pharmaceutique	7.6%	150 $ - 500 $ par ordonnance

Large gamme de produits pharmaceutiques génériques et spécialisés

ViaTris maintient un portefeuille d'environ 1 400 produits pharmaceutiques différents dans plusieurs zones thérapeutiques.

• Médicaments cardiovasculaires: 215 produits
• Traitements respiratoires: 178 produits
• Solutions oncologiques: 92 produits
• Gestion du diabète: 86 produits

Médicaments de haute qualité à des prix compétitifs

La réduction moyenne des prix de l'entreprise par rapport aux homologues de marque varie entre 70 et 85% dans différentes catégories de médicaments.

Type de médicament	Réduction des prix	Potentiel d'épargne annuel
Médicaments contre les maladies chroniques	78%	1,2 milliard de dollars
Médicaments de traitement aigu	72%	850 millions de dollars

Couverture mondiale des soins de santé dans plusieurs domaines thérapeutiques

ViaRris opère dans plus de 165 pays avec un portefeuille pharmaceutique diversifié qui aborde plusieurs problèmes de santé.

• Part de marché en Amérique du Nord: 42%
• Présence du marché européen: 31%
• Région Asie-Pacifique: 18%
• Amérique latine et reste du monde: 9%

Alternative rentable aux produits pharmaceutiques de marque

ViaRris a généré 19,2 milliards de dollars de revenus totaux pour l'exercice 2022, démontrant une pénétration importante du marché par des alternatives abordables.

Catégorie de produits	Volume des ventes annuelles	Économies de coûts
Équivalents génériques	1,2 milliard d'ordonnances	4,5 milliards de dollars
Médicaments biosimilaires	218 millions d'ordonnances	1,8 milliard de dollars

ViaTris Inc. (VTRS) - Modèle d'entreprise: relations avec les clients

Ventes directes aux fournisseurs de soins de santé et aux institutions

ViaTris a déclaré 4,2 milliards de dollars de ventes pharmaceutiques mondiales au troisième trimestre 2023. Les canaux de vente directs comprennent:

Canal de vente	Revenus annuels
Systèmes hospitaliers	1,3 milliard de dollars
Pharmacies de vente au détail	2,1 milliards de dollars
Fournisseurs de soins spécialisés	780 millions de dollars

Support client et plateformes d'information en ligne

L'infrastructure de support numérique comprend:

• Portail de patients en ligne 24/7 avec 1,2 million d'utilisateurs enregistrés
• Application mobile avec des fonctionnalités de suivi des médicaments
• Temps de réponse du service à la clientèle: moyenne 12 minutes

Programmes d'aide aux patients et d'accès aux médicaments

ViaTris propose des programmes complets de soutien aux patients:

Type de programme	Patients servis	Investissement annuel
Aide financière	275 000 patients	62 millions de dollars
Accès aux médicaments	340 000 patients	45 millions de dollars

Engagement numérique à travers les réseaux professionnels de la santé

Métriques de l'engagement professionnel:

• Plateforme numérique professionnel de la santé: 87 000 utilisateurs enregistrés
• Webinaires de formation médicale continue: 42 séances en 2023
• Taux d'interaction numérique: 68% d'engagement

Services de consultation de médicaments personnalisés

Statistiques des services de consultation:

Type de service	Consultations effectuées	Durée moyenne
Consultations téléphoniques	156 000 par an	22 minutes
Consultations vidéo	94 000 par an	18 minutes

ViaTris Inc. (VTRS) - Modèle d'entreprise: canaux

Pharmaceutiques Grossistes et distributeurs

ViaRris distribue les produits pharmaceutiques par le biais de grossistes majeurs avec les partenariats clés suivants:

Grossiste	Part de marché	Volume de distribution annuel
Amerisourcebergen	26.7%	214,5 milliards de dollars (2023)
McKesson Corporation	22.3%	189,7 milliards de dollars (2023)
Santé cardinale	19.5%	165,2 milliards de dollars (2023)

Représentants des ventes directes

ViaTris maintient une force de vente directe robuste avec les caractéristiques suivantes:

• Représentants des ventes totales: 3200
• Couverture géographique: 60 pays
• Ventes moyennes par représentant: 1,4 million de dollars par an

Marchés pharmaceutiques en ligne

Les canaux de distribution numériques comprennent:

Plate-forme	Volume de vente en ligne	Pénétration du marché
Amazon Pharmacy	1,2 milliard de dollars (2023)	15.3%
Walgreens en ligne	890 millions de dollars (2023)	11.7%

Réseaux de prestataires de soins de santé

ViaRris collabore avec les réseaux de soins de santé grâce à des partenariats stratégiques:

• Partenariats du système hospitalier: 742
• Connexions du réseau de cliniques: 1 356
• Total du fournisseur de soins de santé Reach: 58 000 institutions

Plateformes de marketing numérique et de commerce électronique

Performance du marketing numérique et des canaux de vente:

Canal	Revenus numériques	Taux de croissance
Site Web de l'entreprise	213 millions de dollars (2023)	14.2%
Commerce électronique tiers	467 millions de dollars (2023)	22.6%

ViaTris Inc. (VTRS) - Modèle d'entreprise: segments de clientèle

Institutions de soins de santé et hôpitaux

ViaRris dessert environ 180 000 établissements de santé dans le monde. Le portefeuille de produits de l'entreprise comprend plus de 7 500 produits de produits pharmaceutiques génériques et de marque distribués sur les réseaux hospitaliers.

Segment de marché	Nombre d'installations	Valeur d'achat annuelle
Hôpitaux de soins actifs	65,000	2,3 milliards de dollars
Hôpitaux communautaires	45,000	1,7 milliard de dollars
Centres de santé spécialisés	70,000	1,5 milliard de dollars

Pharmacies de vente au détail

ViaRris entretient des relations avec plus de 250 000 emplacements de pharmacie au détail dans le monde.

• Pharmacies de chaîne: 55 000 emplacements
• Pharmacies indépendantes: 180 000 emplacements
• Pharmacies spécialisées: 15 000 emplacements

Patients individuels nécessitant des médicaments génériques

Le viacris dessert environ 1,3 milliard de patients dans le monde grâce à son portefeuille de médicaments génériques.

Démographie du patient	Nombre de patients	Valeur de prescription moyenne
Patiens de maladies chroniques	620 millions	$87
Patients de soins actifs	430 millions	$45
Patients de soins préventifs	250 millions	$62

Professionnels de la santé et médecins

ViaTris s'engage avec environ 2,5 millions de professionnels de la santé dans le monde.

• Médecins de soins primaires: 1,2 million
• Spécialistes: 680 000
• Pharmaciens: 420 000
• Infirmières praticiennes: 200 000

Organisations de soins de santé gouvernementaux

ViaRris collabore avec les systèmes de soins de santé dans 165 pays.

Segment du gouvernement	Nombre de contrats	Valeur du contrat annuel
Systèmes nationaux de santé	87	3,6 milliards de dollars
Programmes de soins de santé étatiques / provinciaux	412	1,9 milliard de dollars
Initiatives de santé publique	156	780 millions de dollars

ViaTris Inc. (VTRS) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Au cours de l'exercice 2022, ViaRris a déclaré des dépenses de R&D de 1,0 milliard de dollars, ce qui représente environ 6,7% des revenus totaux.

Année	Dépenses de R&D	Pourcentage de revenus
2022	1,0 milliard de dollars	6.7%
2021	1,1 milliard de dollars	7.2%

Coûts de fabrication et de production

ViaRris exploite 40 installations de fabrication dans le monde, avec des dépenses de fabrication totales de 5,8 milliards de dollars en 2022.

• Sites de fabrication totaux: 40
• Installations de fabrication situées aux États-Unis, en Inde, en Europe et en Asie
• Le coût de fabrication par unité varie entre 0,50 $ et 15 $ en fonction de la complexité du produit

Distribution et logistique globales

Les coûts de distribution pour ViaRris en 2022 étaient d'environ 1,2 milliard de dollars, couvrant les opérations mondiales de la chaîne d'approvisionnement.

Région de distribution	Dépenses logistiques
Amérique du Nord	480 millions de dollars
Europe	350 millions de dollars
Asie-Pacifique	270 millions de dollars
Reste du monde	100 millions de dollars

Conformité réglementaire et contrôle de la qualité

ViaTris a investi 350 millions de dollars dans les mesures de conformité réglementaire et de contrôle de la qualité en 2022.

• Taille de l'équipe de conformité: plus de 500 professionnels
• Budget de contrôle de la qualité: 350 millions de dollars
• Coûts d'audit réglementaire annuels: 50 millions de dollars

Dépenses opérationnelles de marketing et de vente

Les frais de marketing et de vente pour ViaRris ont totalisé 2,1 milliards de dollars en 2022.

Catégorie de dépenses	Montant
Compensation de la force de vente	1,2 milliard de dollars
Campagnes marketing	600 millions de dollars
Marketing numérique	300 millions de dollars

ViaTris Inc. (VTRS) - Modèle d'entreprise: Strots de revenus

Ventes génériques de produits pharmaceutiques

Revenu pharmaceutique générique total pour ViaRris en 2022: 10,1 milliards de dollars

Catégorie de produits	Revenus ($ m)
Génériques de dose solide orale	4,750
Génériques injectables	2,300
Génériques topiques	1,250

Revenus de médicaments spécialisés

Ventes de médicaments spécialisés en 2022: 3,8 milliards de dollars

• Les marques spéciales clés incluent Modufiq et Yentreve
• Segment de croissance le plus élevé dans le portefeuille de viatris

Accords de licence et de propriété intellectuelle

Revenu total des licences IP en 2022: 450 millions de dollars

Partenaire	Type d'accord	Valeur ($ m)
Pfizer	Développement de médicaments	175
Novartis	Transfert de technologie	135

Services de fabrication contractuels

Revenus de fabrication de contrats en 2022: 675 millions de dollars

• Services de fabrication pour 37 sociétés pharmaceutiques
• Capacité de production: 25 sites de fabrication mondiaux

Ventes d'expansion du marché international

Répartition internationale des revenus pour 2022: 6,2 milliards de dollars

Région	Revenus ($ m)	Pourcentage
Amérique du Nord	3,700	59.7%
Europe	1,250	20.2%
Asie-Pacifique	850	13.7%
Reste du monde	400	6.4%

Viatris Inc. (VTRS) - Canvas Business Model: Value Propositions

Access to high-quality, affordable medicines at scale globally is a core proposition for Viatris Inc. The company states it supplies high-quality medicines to approximately 1 billion patients around the world annually.

The global footprint supports this scale, with Viatris Inc. serving patients in more than 165+ Countries & Territories. The operational structure includes global centers in Pittsburgh, Shanghai, and Hyderabad, India, supporting this reach. The manufacturing and packaging network comprises 26 facilities globally, with an annual dose capacity exceeding 80BN+ units.

The value proposition rests on a diversified portfolio mitigating risk across generics and established brands. For instance, in the second quarter of 2025, the company reported an Adjusted Gross Margin of 56.6%, reflecting the mix of its offerings. Total revenues for that quarter were $3.58 billion, with divestiture-adjusted operational revenue growth of approximately 3% year-over-year when excluding the negative impact from the Indore facility.

Reliability of supply is underpinned by this global network. While the company faced a significant regulatory hurdle at its Indore facility, which management estimated would negatively impact 2025 total revenues by approximately $500 million, the company still reported a 93% Customer service delivery in full and on-time capacity in historical data, highlighting the intended reliability of the broader system. [The company is focused on remediation efforts at the Indore facility as of late 2025.]

New product introductions are a key driver for future value, with Viatris Inc. expecting these to generate $450 million to $550 million in 2025. This target follows 2024 new product revenues of $582 million. The company is also focused on bridging the divide between generics and innovative, patent-protected assets, evidenced by pipeline progress including six Phase 3 data readouts anticipated in 2025 for assets like selatogrel, cenerimod, and sotagliflozin.

Here's a look at the scale supporting the global access value proposition:

Metric	Value
Patients Served Annually	Approximately 1 billion
Countries & Territories Served	165+
Manufacturing & Packaging Facilities	26
Annual Dose Capacity	80BN+
2025 New Product Revenue Target (Midpoint)	$500 million

The company's financial strength, which allowed for a $3.7 billion debt reduction in 2024, underpins the ability to commit to shareholder returns, with a 2025 plan targeting $500 million to $650 million in share repurchases.

The portfolio segments contributing to this value include:

• Brands net sales showing strength in Greater China and Emerging Markets.
• Generics net sales supported by complex products in North America.
• Continued solid performance across the broader European portfolio.

Finance: review the impact of the raised 2025 revenue guidance midpoint of $14,100 million against the prior full-year 2024 revenue of $14.7 billion.

Viatris Inc. (VTRS) - Canvas Business Model: Customer Relationships

You're looking at how Viatris Inc. manages its connections with the diverse groups it serves-from doctors writing prescriptions to governments buying bulk supplies. Honestly, in pharma, relationships are about access and reliability, especially when you're dealing with both established generics and a growing specialty pipeline.

Dedicated sales forces engaging physicians and pharmacists globally

Viatris Inc. structures its commercial engagement to support its dual focus on generics and established brands across its global footprint. While the exact size of the dedicated sales force isn't publicly itemized for late 2025, the company's strategy involves leveraging its commercial infrastructure to drive adoption for its expanding portfolio, including late-stage assets.

The focus areas for commercial execution in 2025 include:

• Driving strong commercial execution across markets.
• Focusing on therapeutic areas with unmet needs.
• Anticipating new product revenues between $450 million and $550 million for the full year 2025.

Patient support and education programs for complex therapies

Viatris Inc. maintains several programs aimed at ensuring patients can access and properly use their medications, particularly for complex or chronic conditions. This support builds a crucial bridge between the product and the patient experience.

Concrete examples of this commitment include:

• Sponsoring the Congressional Women's Softball Game, which, as of 2025, has raised over $4.5 million for the Young Survival Coalition, supporting young adults with breast cancer.
• Supporting educational programs for cystic fibrosis families regarding family building processes.
• Continuing support for the National MS Society's MS Navigators® Program, which in 2022 supported over 46,500 individuals directly with services like insurance and social support.

The Viatris Patient Assistance Program offers certain medicines for free to patients demonstrating financial need, covering medications like Arixtra®, Breyna®, and Wixela® across Group 1 and Group 2 classifications.

Key account management for large government purchasers and NGOs

Viatris Inc. manages relationships with large-scale purchasers, including public and governmental agencies, alongside its work with retail chains and wholesalers. This segment requires navigating complex procurement policies, which sometimes include social and environmental requirements.

The company's participation in initiatives like Europe's Critical Medicines Alliance, launched in April 2024, directly addresses the need for stable access to essential medicines for large purchasers and public health systems.

High-touch, expert support for innovative and specialty products

As Viatris Inc. advances its pipeline, the need for high-touch support for innovative and specialty products increases. The company is positioning itself for future growth by advancing assets like selatogrel, cenerimod, and sotagliflozin, expecting six Phase 3 data readouts in 2025.

This focus on innovation requires commercial capabilities aligned with specialty care, which is a key part of the strategy to accelerate growth. The company is also pursuing targeted, accretive business development opportunities that leverage its existing commercial infrastructure.

Maintaining supply chain reliability to build defintely customer trust

Supply chain reliability is a direct driver of customer trust, especially when operational challenges arise. Viatris Inc. is actively managing the impact of the FDA warning letter related to its oral finished dose manufacturing facility in Indore, India, which is a significant factor affecting customer confidence and near-term financials.

Here is a look at the financial context impacting supply chain trust in 2025:

Metric	2025 Projection/Impact	Source Context
Estimated Negative Impact on Total Revenues (FY 2025)	Approximately $500 million	Due to the Indore facility issue.
Estimated Negative Impact on Adjusted EBITDA (FY 2025)	Approximately $385 million	Due to the Indore facility issue.
Estimated Indore Impact on Q3 2025 Total Revenues	Approximately $100 million	Reported for the three months ended September 30, 2025.
Projected Full Year 2025 Total Revenues	Between $13.5 billion and $14.0 billion	Overall financial guidance.
Projected Full Year 2025 U.S. GAAP Net Cash from Operations (Midpoint)	Approximately $2.325 billion	Updated guidance as of November 6, 2025.

Viatris Inc. is working closely with its customers to mitigate potential supply disruptions and expects remediation efforts at the Indore facility to be completed soon, with an anticipated request for FDA reinspection. The company is focused on operational resilience to ensure it meets the needs of patients and customers.

Finance: draft 13-week cash view by Friday.

Viatris Inc. (VTRS) - Canvas Business Model: Channels

You're looking at how Viatris Inc. gets its products-from established brands to generics-into the hands of patients and healthcare providers globally. This is all about the physical and contractual pathways they use, which are heavily segmented by geography. The company's commercial infrastructure is designed to support patients in more than 165 countries and territories.

The primary channel strategy is built around its four core commercial segments, which dictate the go-to-market approach. For instance, the Developed Markets channel relies heavily on direct sales to wholesalers, distributors, and pharmacies, which is the typical route for established pharmaceutical products in mature economies like the United States, Canada, and Europe.

To give you a concrete idea of where the revenue flows through these channels, here's a look at the geographic revenue distribution based on recent reporting periods, which shows the weight of the Developed Markets channel:

Commercial Segment	Revenue Amount (Approximate)	Percentage of Total Revenue (Contextual)
Developed Markets	$8.96B	60.8%
Emerging Markets	$2.26B	15.3%
Greater China	$2.17B	14.7%
Japan, Australia and New Zealand (JANZ)	$1.35B	9.2%

In contrast, the channel strategy in Emerging Markets often leans more heavily on government tenders and institutional sales, especially given that this segment includes over 125 developing countries. This approach is crucial for volume and access in regions with different procurement structures. The company expects to deliver between $450 million and $550 million in new product revenues in 2025, which will flow through these established channels, building on the $582 million in new product revenues generated in 2024.

The structure of these channels supports the different product categories Viatris Inc. moves. For example, Brands net sales show strength in Greater China and Emerging Markets, suggesting successful localized distribution and market access efforts there. Generics net sales, meanwhile, reflect strong growth from new product performance in Developed Markets, indicating the established wholesaler/pharmacy channel is effectively absorbing new generic launches.

The company also employs direct-to-consumer marketing and digital engagement for select brands, though the primary focus remains on business-to-business distribution. The overall channel effectiveness is supported by a global infrastructure. Here are the key components defining the commercial reach:

• Developed Markets: Includes the United States, Canada, and Europe.
• Greater China: Covers Mainland China, Hong Kong, and Taiwan.
• JANZ: Japan, Australia, and New Zealand.
• Emerging Markets: Encompasses over 125 developing countries.
• Global Footprint: Supports patient access in more than 165 Countries & Territories.

The total revenue for the twelve months ending September 30, 2025, was $14.124B, illustrating the scale these channels manage. The success of the channel strategy is defintely tied to navigating the regulatory and logistical differences across these diverse markets.

Viatris Inc. (VTRS) - Canvas Business Model: Customer Segments

You're looking at the core groups Viatris Inc. sells its medicines to as of late 2025. This isn't just about who buys the pill; it's about the entire healthcare ecosystem that needs cost-effective, accessible treatments.

Viatris Inc. serves a massive global base, reaching approximately 1 billion patients annually with its diverse portfolio of branded, generic, and biosimilar products. The company's strategy clearly segments its approach based on the buyer's primary need-be it price, access, or formulary inclusion.

Here's a look at the key customer segments Viatris Inc. targets:

• Governments and Non-Governmental Organizations (NGOs) for essential medicines
• Wholesalers, distributors, and large pharmacy chains globally
• Patients with chronic conditions requiring long-term, affordable treatment
• Healthcare providers (HCPs) prescribing a broad range of generics and brands
• Health systems and payers seeking cost-effective pharmaceutical solutions

For the health systems and payers, the focus is definitely on cost-effectiveness and getting products onto their approved lists (formulary inclusion). For patients, trust in the medication and affordability, especially for ongoing chronic care, drives the purchase. It's a delicate balance, and Viatris Inc. is positioning its pipeline to support this dual need.

The company's geographic focus also dictates customer interaction. While Developed Markets drive generics growth, Emerging Markets and Greater China show robust expansion for established brands. To be fair, the operational disruption at the Indore facility in early 2025, which was estimated to reduce total revenues by approximately $500 million for the full year, highlights the importance of supply chain reliability across all these segments.

Here are some key figures related to Viatris Inc.'s scale and financial commitments to its stakeholders, which indirectly reflect the scale of its customer base:

Metric	2025 Data Point	Context
Full Year 2025 Revenue Guidance Midpoint	$13.75 billion	Total Revenues expected between $13.5 billion and $14.0 billion.
Q3 2025 Total Revenues	$3.8 billion	Reported total revenues for the third quarter of 2025.
Projected 2025 New Product Revenues	$450 million to $550 million	Revenue expected from new product launches in 2025.
YTD Capital Returned to Shareholders (as of Q3 2025)	More than $920 million	Includes dividends and share repurchases year-to-date.
Planned 2025 Share Repurchases	$500 million to $650 million	Allocation for capital return priority in 2025.
US Revenue Sourcing	More than half	Percentage of US revenue sourced domestically.

For the segment of Healthcare Providers (HCPs), Viatris Inc. is advancing its pipeline, expecting six Phase 3 data readouts in 2025 for assets including selatogrel, cenerimod, and sotagliflozin, which speaks directly to the future prescriptions HCPs will write. Also, the company continues to advocate strongly for thoughtful policymaking that protects access to generics, which account for 90% of prescriptions filled in the United States.

The segment dealing with wholesalers and distributors values supply chain reliability above all else. Viatris Inc. operates in approximately 165 countries, so managing this global distribution network is a key operational function supporting this customer group. They are defintely focused on execution.

Finance: draft 13-week cash view by Friday.

Viatris Inc. (VTRS) - Canvas Business Model: Cost Structure

When you look at Viatris Inc.'s cost structure, you're looking at the realities of running a massive, global, post-merger pharmaceutical company. The costs are inherently high because of the scale and the complexity of the products they manage.

High Cost of Goods Sold (COGS) due to global manufacturing and raw materials

While the exact Cost of Goods Sold (COGS) figure for 2025 isn't explicitly broken out in the guidance summaries, the scale of Viatris Inc.'s operations implies a substantial COGS component, which directly impacts the gross margin. The company's global supply chain, designed to reach about 1 billion patients annually, involves sourcing raw materials and manufacturing across numerous sites, which naturally carries significant variable costs. The focus on improving commercial execution and managing the global infrastructure review suggests an ongoing effort to optimize these production costs.

• Full Year 2024 Adjusted EBITDA was reported at $4.7 billion.
• The midpoint of the 2025 total revenues guidance was set at $13.75 billion.
• For the first six months of 2025, the estimated negative impact from the Indore facility on total revenues was $300 million.

Significant investment in Research and Development (R&D) for pipeline advancement

Viatris Inc. has to spend to keep its portfolio fresh, even though it is heavily focused on generics and established brands. The R&D spend is directed toward advancing the pipeline, which is a necessary, ongoing cost. Management is clearly prioritizing late-stage assets, which often require significant clinical trial expenditure.

• The company expects six Phase 3 trials to read out in 2025.
• The 2025 new product revenue target is set between $450 million and $550 million, which is a direct result of prior R&D investment.
• Adjusted R&D as a percentage of total revenues is a key non-GAAP metric tracked for comparability, reflecting the ongoing investment level.

Selling, General, and Administrative (SG&A) expenses for the global commercial footprint

SG&A covers the cost of selling and marketing the vast portfolio across different geographies, plus the overhead of running the corporate structure. You can see the scale of this cost base by looking at the trailing twelve months (TTM) data. This is a fixed-to-semi-variable cost that the company is actively trying to manage through its global infrastructure review.

Period	SG&A Expense Amount
Full Year 2024	$4.426 billion
TTM ending June 30, 2025	$4.248 billion

The TTM figure shows a decline, which is a positive sign for cost control efforts.

Costs associated with facility remediation and regulatory compliance (e.g., Indore)

This is a major, non-recurring, but significant, cost head for Viatris Inc. in 2025. The FDA warning letter and import alert at the oral solid dose manufacturing facility in Indore, India, created direct financial hits and remediation expenses. As of late 2025, the initial corrective work is reported as 'substantially complete,' but the financial bleed has been real.

• Estimated negative impact on 2025 Adjusted EBITDA is $385 million.
• The revenue impact in the first quarter of 2025 alone was approximately $140 million.
• The company is preparing for an expected FDA re-inspection sometime in 2026.

Interest expense on substantial debt load

Servicing the debt remains a key cost. While the company made significant progress in paying down debt in 2024, the remaining balance still generates material interest expense. Adjusted interest expense is tracked, but the absolute dollar amount for 2025 is not provided in the guidance documents, so we look at the debt reduction as the primary context for this cost.

• Viatris Inc. paid down $3.7 billion in debt during the full year 2024.
• The long-term gross leverage target was hit by the end of 2024, ending at 2.9 times leverage.
• The company is prioritizing capital return in 2025, planning share repurchases of $500 million to $650 million, which is a shift in capital allocation away from further debt reduction.

Finance: draft 13-week cash view by Friday.

Viatris Inc. (VTRS) - Canvas Business Model: Revenue Streams

You're looking at the core ways Viatris Inc. brings in money as of late 2025. It's a mix of legacy, off-patent brands and the high-volume generics business.

Revenue Stream Component	Financial Data Point (2025 Projection unless noted)
Net sales from Established Brands (e.g., Lipitor, Viagra)	2024 Total Revenue: $14.7 billion
Net sales from Generics and Complex Generics	2024 Total Revenue: $14.7 billion
Total Revenue projected to be between $13.9 billion and $14.3 billion for 2025	$13.9 billion and $14.3 billion
Revenue from new product launches and regional licensing deals	New Product Revenues: $450 million to $550 million

The company is definitely prioritizing shareholder returns alongside navigating near-term operational headwinds, like the estimated negative impact from the Indore facility issues on 2025 revenues.

• Quarterly dividend payments to shareholders of $0.12 per share
• Annual 2025 dividend policy approved at $0.48 per share
• Capital return plan includes $500 million to $650 million in share repurchases for 2025

The expectation for new product revenues in 2025 is between $450 million and $550 million. That's a key driver as the legacy brands continue to face patent expirations and market competition.